Cristina Ripoll

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7039210/publications.pdf

Version: 2024-02-01

67 papers	5,278 citations	147566 31 h-index	114278 63 g-index
75 all docs	75 docs citations	75 times ranked	4377 citing authors

#	Article	IF	Citations
1	Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. Gastroenterology, 2007, 133, 481-488.	0.6	926
2	Baveno VII â€“ Renewing consensus in portal hypertension. Journal of Hepatology, 2022, 76, 959-974.	1.8	890
3	Esophageal Eosinophilic Infiltration Responds to Proton Pump Inhibition in Most Adults. Clinical Gastroenterology and Hepatology, 2011, 9, 110-117.	2.4	354
4	Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. Journal of Hepatology, 2009, 50, 923-928.	1.8	340
5	Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. Clinical Gastroenterology and Hepatology, 2009, 7, 689-695.	2.4	215
6	Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology, 2005, 42, 793-801.	3.6	213
7	Comparison of Transcatheter Arterial Embolization and Surgery for Treatment of Bleeding Peptic Ulcer after Endoscopic Treatment Failure. Journal of Vascular and Interventional Radiology, 2004, 15, 447-450.	0.2	183
8	Portal Hypertensionâ€“Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. Clinical Gastroenterology and Hepatology, 2008, 6, 1412-1417.	2.4	175
9	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	0.6	162
10	Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis. American Journal of Gastroenterology, 2006, 101, 2269-2274.	0.2	150
11	Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis. American Journal of Gastroenterology, 2007, 102, 1116-1126.	0.2	137
12	Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine, 2018, 30, 138-147.	2.7	116
13	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	1.8	97
14	Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. European Journal of Radiology, 2005, 55, 120-124.	1.2	95
15	The heart in liver transplantation. Journal of Hepatology, 2011, 54, 810-822.	1.8	84
16	Cardiac Dysfunction During Liver Transplantation: Incidence and Preoperative Predictors. Transplantation, 2008, 85, 1766-1772.	0.5	77
17	The management of portal hypertensive gastropathy and gastric antral vascular ectasia. Digestive and Liver Disease, 2011, 43, 345-351.	0.4	67
18	Oral probiotic <scp>VSL</scp>#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver International, 2014, 34, 1504-1512.	1.9	61

#	Article	IF	Citations
19	Validation of Noninvasive Indices of Global Systolic Function in Patients With Normal and Abnormal Loading Conditions. Circulation: Cardiovascular Imaging, 2014, 7, 164-172.	1.3	55
20	Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transplantation, 2009, 15, 530-539.	1.3	52
21	Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats â€“ Improving Yield and Reproducibility. Scientific Reports, 2018, 8, 9163.	1.6	49
22	Use of Everolimus as a Rescue Immunosuppressive Therapy in Liver Transplant Patients With Neoplasms. Transplantation, 2007, 84, 786-791.	0.5	48
23	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology, 2013, 58, 2079-2088.	3.6	48
24	Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. Liver Transplantation, 2009, 15, 1247-1253.	1.3	46
25	Hepatic Venous Pressure Gradient and Outcomes in Cirrhosis. Journal of Clinical Gastroenterology, 2007, 41, S330-S335.	1.1	45
26	Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. Hepatology, 2017, 65, 2019-2030.	3.6	43
27	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	2.4	42
28	Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis. Journal of Clinical Gastroenterology, 2015, 49, 613-619.	1.1	40
29	Management of Gastropathy and Gastric Vascular Ectasia in Portal Hypertension. Clinics in Liver Disease, 2010, 14, 281-295.	1.0	39
30	Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scandinavian Journal of Gastroenterology, 2013, 48, 487-495.	0.6	38
31	Prevalence of portal hypertensive duodenopathy in cirrhosis: clinical and haemodynamic features. European Journal of Gastroenterology and Hepatology, 2006, 18, 649-653.	0.8	35
32	Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. Scandinavian Journal of Gastroenterology, 2012, 47, 204-211.	0.6	29
33	The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut, 2007, 56, 259-264.	6.1	24
34	Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver International, 2018, 38, 102-112.	1.9	21
35	Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension. Current Treatment Options in Gastroenterology, 2007, 10, 483-494.	0.3	18
36	Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World Journal of Transplantation, 2014, 4, 133.	0.6	18

#	Article	IF	Citations
37	Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis. PLoS ONE, 2017, 12, e0171260.	1.1	17
38	Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. Liver International, 2008, 28, 1129-1135.	1.9	16
39	A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl4-cirrhotic liver. Liver International, 2010, 30, 988-994.	1.9	16
40	Clinical Utility of a Riskâ€Adapted Protocol for the Evaluation of Coronary Artery Disease in Liver Transplant Recipients. Liver Transplantation, 2019, 25, 1177-1186.	1.3	16
41	The interpretation of hepatic venous pressure gradient tracings â€“ excellent interobserver agreement unrelated to experience. Liver International, 2016, 36, 1160-1166.	1.9	12
42	Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma. Frontiers in Oncology, 2019, 9, 785.	1.3	12
43	Serum Ferritin in Patients With Cirrhosis is Associated With Markers of Liver Insufficiency and Circulatory Dysfunction, but Not of Portal Hypertension. Journal of Clinical Gastroenterology, 2015, 49, 784-789.	1.1	11
44	Hepatic Arterial Vasodilation Is Independent of Portal Hypertension in Early Stages of Cirrhosis. PLoS ONE, 2015, 10, e0121229.	1.1	11
45	Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension. Liver International, 2015, 35, 353-361.	1.9	11
46	Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. Liver International, 2020, 40, 3093-3102.	1.9	11
47	Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. Liver International, 2016, 36, 232-239.	1.9	10
48	Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. Clinical and Translational Gastroenterology, 2019, 10, e00002.	1.3	10
49	Effect of ETâ€A blockade on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study. Liver International, 2021, 41, 554-561.	1.9	10
50	Cardiac function, A key component in evaluation for liver transplant. Liver Transplantation, 2018, 24, 7-8.	1.3	8
51	Isolated bacterial infection without decompensation has no impact on survival of compensated patients with cirrhosis. Liver International, 2021, 41, 1370-1378.	1.9	7
52	Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score. Zeitschrift Fur Gastroenterologie, 2018, 56, 461-468.	0.2	5
53	Prognostic Factors in Compensated and Decompensated Cirrhosis. Current Hepatology Reports, 2014, 13, 171-179.	0.4	4
54	Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.6	4

#	Article	IF	Citations
55	Does interferon improve portal hypertension?. Journal of Antimicrobial Chemotherapy, 2006, 58, 7-12.	1.3	3
56	Prognostic Markers in Patients Who Have Recovered from an Acute Variceal Bleeding: Role of HVPG Measurement. Disease Markers, 2011, 31, 165-169.	0.6	3
57	Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. Hepatology Communications, 2021, 5, 1755-1766.	2.0	3
58	Pressure volume curves in cirrhosis: More than meets the eye. Journal of Hepatology, 2017, 67, 656-657.	1.8	2
59	Reply to: â€˜Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinomaâ€™. Journal of Hepatology, 2022, 77, 567-568.	1.8	2
60	Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis. , 2016, , 333-339.		1
61	It takes two â€œeyesâ€• to see in depth. Journal of Hepatology, 2019, 70, 790-791.	1.8	1
62	First things first! Can bacterial infections be considered as decompensating events per se?. Journal of Hepatology, 2021, 75, 1241-1242.	1.8	1
63	Early transplanted liver performance and indocyanine green clearance. Liver Transplantation, 2010, 16, n/a-n/a.	1.3	0
64	Reply. Hepatology, 2014, 60, 1795-1796.	3.6	0
65	The advantage of calling things by the same name. Liver Transplantation, 2018, 24, 581-582.	1.3	0
66	Open or closed window: That is the question. Journal of Hepatology, 2021, 74, 485-486.	1.8	0
67	Secondary Prophylaxis in Special Patient Populations. , 2016, , 317-332.		0